Agenus Inc. stock is down -0.31% since 30 days ago. The next earnings date is Mar 12, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 16.67% of the previous 23 December’s closed higher than November.
Agenus Inc. discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer.